Radioimmunotherapy of patients with cutaneous T-cell lymphoma using an iodine-131-labeled monoclonal antibody: analysis of retreatment following plasmapheresis
Journal Article
·
· J. Nucl. Med.; (United States)
OSTI ID:5234522
Radioimmunotherapy retreatment of patients receiving radiolabeled murine monoclonal antibodies is difficult because of human antimurine antibody (HAMA) formation. Retreatment therapy was initiated in three patients at the time of disease progression using a radioiodinated monoclonal antibody (T101). The clinical protocol consisted of a two day plasma exchange (4-6 L) to reduce HAMA titers. Immunoimaging was performed with 5 mCi /sup 131/I-T101 (10 mg). Gamma scintillation images were obtained 18 hr postinfusion, and radiation dosimetry estimates were performed. At 24 hr postinfusion, each patient received a 100-mCi /sup 131/I-T101 (10 mg) therapy dose. Results obtained after plasmapheresis showed a significant reduction, ranging from 28%-61%, in HAMA titers. Blood clearances were markedly different between initial therapy and retreatment therapy for patient with high HAMA titers, reflecting immune complex formation. Two patients responded to retreatment therapy with responses lasting 1 to 2 mo. Minimal acute and no chronic toxicities were observed during the retreatment protocol.
- Research Organization:
- Northwestern Univ. Medical Center, Chicago, IL (USA)
- OSTI ID:
- 5234522
- Journal Information:
- J. Nucl. Med.; (United States), Journal Name: J. Nucl. Med.; (United States) Vol. 29:2; ISSN JNMEA
- Country of Publication:
- United States
- Language:
- English
Similar Records
Radioimmunodetection and radioimmunotherapy of cutaneous T cell lymphomas using an /sup 131/I-labeled monoclonal antibody: an Illinois Cancer Council Study
Long-term persistence of human anti-murine antibody responses following radioimmunodetection and radioimmunotherapy of cutaneous T-cell lymphoma patients using /sup 131/I-T101
Human anti-murine antibody responses in ovarian cancer patients undergoing radioimmunotherapy with the murine monoclonal antibody OC-125
Journal Article
·
Tue Mar 31 23:00:00 EST 1987
· J. Clin. Oncol.; (United States)
·
OSTI ID:6521243
Long-term persistence of human anti-murine antibody responses following radioimmunodetection and radioimmunotherapy of cutaneous T-cell lymphoma patients using /sup 131/I-T101
Journal Article
·
Mon Oct 31 23:00:00 EST 1988
· Exp. Hematol.; (United States)
·
OSTI ID:6555132
Human anti-murine antibody responses in ovarian cancer patients undergoing radioimmunotherapy with the murine monoclonal antibody OC-125
Journal Article
·
Wed Aug 01 00:00:00 EDT 1990
· Gynecologic Oncology; (USA)
·
OSTI ID:6758754
Related Subjects
550604* -- Medicine-- Unsealed Radionuclides in Therapy-- (1980-)
62 RADIOLOGY AND NUCLEAR MEDICINE
ANTIBODIES
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BLOOD-PLASMA CLEARANCE
CLEARANCE
DAYS LIVING RADIOISOTOPES
DISEASES
DOSES
IMMUNOLOGY
INTERMEDIATE MASS NUCLEI
IODINE 131
IODINE ISOTOPES
ISOTOPES
LABELLING
LYMPHOMAS
MEDICINE
MONOCLONAL ANTIBODIES
NEOPLASMS
NUCLEAR MEDICINE
NUCLEI
ODD-EVEN NUCLEI
PATIENTS
RADIATION DOSES
RADIOIMMUNOLOGY
RADIOIMMUNOTHERAPY
RADIOISOTOPES
RADIOLOGY
RADIOTHERAPY
THERAPY
62 RADIOLOGY AND NUCLEAR MEDICINE
ANTIBODIES
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BLOOD-PLASMA CLEARANCE
CLEARANCE
DAYS LIVING RADIOISOTOPES
DISEASES
DOSES
IMMUNOLOGY
INTERMEDIATE MASS NUCLEI
IODINE 131
IODINE ISOTOPES
ISOTOPES
LABELLING
LYMPHOMAS
MEDICINE
MONOCLONAL ANTIBODIES
NEOPLASMS
NUCLEAR MEDICINE
NUCLEI
ODD-EVEN NUCLEI
PATIENTS
RADIATION DOSES
RADIOIMMUNOLOGY
RADIOIMMUNOTHERAPY
RADIOISOTOPES
RADIOLOGY
RADIOTHERAPY
THERAPY